Medtronic (NYSE:MDT) announced today that it recently submitted its Hugo surgical robot platform to the FDA for a urologic ...

Patients with intermediate- or high-complexity renal tumors generally have similar outcomes with RAPN and OPN, data suggest.

Medtronic , a global leader in healthcare technology, today announced that the Expand URO Investigational Device Exemption ...

Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced that the Expand URO Investigational Device ...

The prospective, multi-center, single-arm IDE study included 137 patients who underwent urologic procedures using the Hugo™ robotic-assisted ... 1.9% nephrectomy, and 17.9% cystectomy) were ...

Safety: The rates of grade 3 or higher complications (3.7% prostatectomy, 1.9% nephrectomy ... surgeons in the U.S. long-awaited choice in robotic technology," said James Porter, M.D., chief ...

The prospective, multi-center, single-arm IDE study included 137 patients who underwent urologic procedures using the Hugo robotic-assisted ... (3.7% prostatectomy, 1.9% nephrectomy, and 17.9 ...

Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic ...

Q1 2025 Earnings Call Transcript April 22, 2025 Intuitive Surgical, Inc. beats earnings expectations. Reported EPS is $1.81, ...

Largest multi-center prospective Investigational Device Exemption (IDE) study for multi-port robotic-assisted urologic ... (3.7% prostatectomy, 1.9% nephrectomy, and 17.9% cystectomy) were ...